LSBio IHC-plus antibodies

LSBio’s IHC-plus antibodies have been tested and identified as being optimal for use in immunohistochemistry (IHC) against formalin-fixed paraffin-embedded (FFPE) human tissues under LSBio’s standardised IHC-plus immunohistochemistry protocol. Each antibody is tested at multiple concentrations on more than 20 normal human tissue types and, when appropriate, multiple normal brain regions and/or cancer types.

The company’s IHC protocol has been developed over the past 15 years for immunolabelling FFPE tissues, the most common fixation method used by pathology labs worldwide. A LifeSpan pathologist, with extensive experience evaluating IHC, analyses the localisation profile of each antibody, identifying positive and negative cell types, signal strength, subcellular and extracellular staining, and staining artefacts. This information is then compared with all published expression and localisation data available for the protein. This enables LSBio to evaluate how each antibody behaves in IHC, including its specificity to the target protein, its sensitivity of detection and any non-specific staining characteristics that it may display.

In order to be selected as an IHC-plus brand antibody, antibodies must have a close correlation to the published literature, be high affinity, display minimal staining artefacts and have a high signal-to-noise ratio, such that its specific staining is considerably higher than its level of nonspecific background staining.